glp 1 google scholar Frontiers Bridging the gap between GLP1-receptor
Description
Weight loss applications face routine denials
Winther JB, Holst JJ
The approval gives Ozempic (semaglutide) the broadest label in the class, coming after earlier approvals for type 2 diabetes itself and cardiovascular risk reduction in diabetics with known heart disease
GLP-1s also lower heart disease risk in people who have obesity but not diabetes, according to new research published in the Journal of Diabetes
